Search Our Scientific Publications & Authors

J Am Acad Dermatol 2020 Jun 27. Epub 2020 Jun 27.

Hospital Universitario Infanta Leonor. Calle Gran Vía del Este, 80. CP 28031. Madrid, SPAIN.

Br J Dermatol 2020 Jun 29. Epub 2020 Jun 29.

Laboratory of Investigative Dermatology, The Rockefeller University, Rockefeller, NY, USA.

Background: There is a need for valid and reliable biomarkers in hidradenitis suppurativa (HS) for diagnosis and disease activity monitoring. Imaging-based biomarkers have the potential to fulfill this unmet need but no evaluation of analytical or clinical validity has yet been undertaken.

Objectives: To evaluate the analytical and clinical validity of sonographic epidermal thickness, Doppler ultrasound and dermal tunnel diameter in patients with Hidradenitis Suppurativa. Read More

Br J Dermatol 2020 Jun 29. Epub 2020 Jun 29.

Department of Dermatology, Zealand University Hospital, Health Sciences Faculty, University of Copenhagen, Roskilde, Denmark.

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that is not well understood. The HS core outcome set calls for a patient global assessment (PtGA), for which measures are limited.

Objectives: Our aim is to assess the validity, reliability, and responsiveness of a candidate single-item PtGA for HS-specific health-related quality of life (HRQOL). Read More

Br J Dermatol 2020 Jun 29. Epub 2020 Jun 29.

Patientforeningen HS, Copenhagen, Denmark.

The management of hidradenitis suppurativa (HS), a chronic inflammatory skin disease, deserves special consideration in the context of the Coronavirus 2019 (COVID-19) pandemic. A new Global Hidradenitis Suppurativa COVID-19 Registry has been developed to capture data on risks, clinical course, and outcomes of COVID-19 in HS patients. Caused by the virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), COVID-19 is an easily transmissible disease which, in its most severe form, is characterized by respiratory failure and multiple organ dysfunction triggered by a cytokine storm response that predominates in older adults and those with significant comorbidities. Read More

Urology 2020 Jun 25. Epub 2020 Jun 25.

Harvard Medical School, Boston, Mass; Division of Plastic Surgery, Brigham & Women's Hospital, Boston, Mass. Electronic address:

Dermatol Ther 2020 Jun 26. Epub 2020 Jun 26.

Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy.

Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory, disease of the hair follicle. Intralesional corticosteroid treatment in HS patients has been reported, and while several data described this route of administration as an efficient delivery system, its efficacy is still debated.

Objective: The aim of this study was to explore the clinical efficacy and the effect on quality of life (QoL) of an innovative intralesional treatment in HS patients. Read More

Dermatol Ther 2020 Jun 26:e13900. Epub 2020 Jun 26.

Dermatology, Emek Medical Center, Israel.

J Invest Dermatol 2020 Jun 17. Epub 2020 Jun 17.

Laboratory of Investigative Dermatology, Rockefeller University, New York, USA. Electronic address:

J Invest Dermatol 2020 Jun 20. Epub 2020 Jun 20.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:

Skin Res Technol 2020 Jun 25. Epub 2020 Jun 25.

UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

J Eur Acad Dermatol Venereol 2020 Jun 24. Epub 2020 Jun 24.

Psoriasis Research and Treatment Centre, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Hidradenitis suppurativa (HS) is a chronic, inflammatory disease affecting the intertriginous skin of axillary, inguinal, and perianal sites. In these areas, patients develop painful and disabling skin lesions such as inflamed nodules, abscesses, and fistula with foul-smelling secretions. We aimed to investigate the documented prevalence and health care of HS patients in Germany. Read More

Br J Dermatol 2020 Jun 24. Epub 2020 Jun 24.

Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.

Hidradenitis suppurativa (HS) is a chronic inflammatory disease that affects the hair follicle in the apocrine gland-bearing regions. Although HS is not primarily caused by bacterial infection, antibiotics represent the first line treatment in the management of HS primarily for their anti-inflammatory properties, with additional contributions via antimicrobial and immunomodulatory effects. Read More

Int J Dermatol 2020 Jun 23. Epub 2020 Jun 23.

Division of Dermatology, Women's College Hospital, Toronto, ON, Canada.

Actas Dermosifiliogr 2020 Jun 19. Epub 2020 Jun 19.

Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, España. Electronic address:

Spironolactone is an economical potassium-sparing diuretic with an anti-androgenic effect and a good safety profile. Our experience suggests that this diuretic is underexploited in dermatology even though there is evidence supporting its use in several skin conditions. When prescribed for acne in female patients (level 1-2 evidence; strength of recommendation, B), for example, it can reduce the need for antibiotics and possibly isotretinoin. Read More

J Invest Dermatol 2020 Jul;140(7):1323-1326

Division of Dermatology, Department of Medicine, University of Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada. Electronic address:

Current ex vivo and animal models of hidradenitis suppurativa (HS) display issues with fidelity and validity to human disease. Vossen et al.'s Transwell culture system holds potential to reliably assess mechanistic pathways in HS. Read More

Australas J Dermatol 2020 Jun 22. Epub 2020 Jun 22.

Departments of, Department of, Dermatology, Hospital Universitari Arnau de Vilanova de Lleida, Catalonia, Spain.

Case Rep Obstet Gynecol 2020 3;2020:6283720. Epub 2020 Jun 3.

Veracity Clinical Research, Suite 18 Level 1 250 Ipswich Rd., Woolloongabba QLD 4102, Australia.

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, relapsing inflammatory skin condition characterised by the presence of painful nodules, abscesses, and sinus tracts or scarring. Affecting up to 4% of the population, it is not uncommon and is seen predominantly in females at a ratio of 3 : 1. HS carries a substantial burden for those who suffer from it, from the significant psychosocial impact, to the cost of the multitude of topical and systemic treatments which often do not successfully control its symptoms. Read More

Indian J Dermatol 2020 May-Jun;65(3):231-232

Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan E-mail:

J Am Acad Dermatol 2020 Jun 18. Epub 2020 Jun 18.

Department of Dermatology, Hôpital Saint Louis, AP-HP, Paris; Université de Paris, Paris; laboratory of Genetics of Skin Diseases, UMR Inserm U1163, Institut Imagine, Paris, France. Electronic address:

Exp Dermatol 2020 Jun 21. Epub 2020 Jun 21.

Internal Medicine, Hospital Universitario Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Cantabria, Spain.

Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with insulin resistance (IR). Retinol binding protein 4 (RBP4) and ghrelin are two bioactive proteins that have been involved in glucose metabolism and IR, but also in the regulation of immune and inflammatory processes.The aim of this study was to determine the serum levels of RBP4 and ghrelin in patients with HS, and toassessthe possiblerelationship between these levels andIR, disease severity and HS risk. Read More

J Am Acad Dermatol 2020 Jun 17. Epub 2020 Jun 17.

Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, King's College London and Guy's & St Thomas' NHS Foundation Trust, London, UK.

Dermatol Ther 2020 Jun 19:e13877. Epub 2020 Jun 19.

Faculty of Health, University Witten/Herdecke, Witten, Germany.

Hidradenitis suppurativa/ acne inversa (HS/AI) is one of the most debilitating dermatoses with a strong negative impact on every dimension of quality of life. Treatment is dependent on the severity of clinical manifestations and comorbidities. While anti-inflammatory and antimicrobial approaches are recommended for mild and moderate stages, immunomodulatory drugs have gained increasing interest in all stages of HS/AI. Read More

Dermatol Ther 2020 Jun 19:e13875. Epub 2020 Jun 19.

Department of Dermatology at Hospital Universitario Virgen de las Nieves, Granada, Spain.

Dermatol Ther 2020 Jun 18:e13868. Epub 2020 Jun 18.

Dermatology and Venereology Clinic, Emek Medical Center, Afula, Israel.

Acta Derm Venereol 2020 Jun 18. Epub 2020 Jun 18.

Department of Dermatology, University of Oulu, Oulu, Finland.

Actas Dermosifiliogr 2020 Jun 15. Epub 2020 Jun 15.

Unidad de Gestión Clínica de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Puerta del Mar, Cádiz, España.

Int J Mol Sci 2020 Jun 13;21(12). Epub 2020 Jun 13.

Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.

Notch signaling orchestrates the regulation of cell proliferation, differentiation, migration and apoptosis of epidermal cells by strictly interacting with other cellular pathways. Any disruption of Notch signaling, either due to direct mutations or to an aberrant regulation of genes involved in the signaling route, might lead to both hyper- or hypo-activation of Notch signaling molecules and of target genes, ultimately inducing the onset of skin diseases. The mechanisms through which Notch contributes to the pathogenesis of skin diseases are multiple and still not fully understood. Read More

Dermatol Ther 2020 Jun 16:e13845. Epub 2020 Jun 16.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

Dermatol Ther 2020 Jun 15:e13839. Epub 2020 Jun 15.

Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Exp Ther Med 2020 Jul 4;20(1):9-11. Epub 2020 May 4.

Research Laboratory, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.

J Eur Acad Dermatol Venereol 2020 Jun 13. Epub 2020 Jun 13.

European Hidradenitis Suppurativa Foundation e.V, Dessau, Germany.

For the second year in a row the European Academy of Dermatology and Venereology (EADV) School on Hidradenitis suppurativa/acne inversa (HS), which took place on February 3-4, 2020 in Athens with the participation of 4 specialists and 20 residents (17 female, 7 male; Table 1) systematically assessed its effect on the participants knowledge. The global immediate learning efficacy outcome of the two-day theoretical and practical course was evaluated in a voluntary, anonymous, prospective interventional study. A questionnaire with 50 course-relevant questions was distributed to all participants at the beginning and the end of the course for the purpose of self-assessment. Read More

Dermatol Ther 2020 Jun 12:e13824. Epub 2020 Jun 12.

Department of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Bari, Bari, Italy.

Topical antibiotic therapy is a central component of patient management for several skin conditions, including acne, hidradenitis suppurativa, rosacea, impetigo or other superinfected dermatitis, prevention of wound infections. Moreover, particular situations, such as skin diseases of bacterial origin in pregnancy and infants often warrant topical therapy. However, the occurrence of local delayed hypersensitivity reactions and the rising rate of antibiotic resistance are becoming great challenges faced by many dermatologists today. Read More

J Eur Acad Dermatol Venereol 2020 Jun 12. Epub 2020 Jun 12.

Instituto de Investigación Biosanitaria Granada, Granada, Spain.

Background: Hidradenitis suppurativa (HS) can cause considerable impact on several aspects of quality of life. Sexuality is a central aspect of quality of life. In recent years there has been an increase in the number of articles on HS and sexuality. Read More

J Eur Acad Dermatol Venereol 2020 Jun 12. Epub 2020 Jun 12.

Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, United States.

Background: Hidradenitis suppurativa (HS) has been associated with auto-inflammatory conditions, yet the risk of developing connective tissue disease (CTD), morphea, and systemic vasculitis has not been well-characterized.

Objectives: We sought to evaluate the risk of developing CTD, morphea and systemic vasculitis in patients with HS.

Methods: Using claims data we identified patients with HS and used 2:1 risk-set sampling to identify patients without HS. Read More

Aliment Pharmacol Ther 2020 Jul 11;52(2):303-310. Epub 2020 Jun 11.

Department of Dermatology, Cochin Hospital, AP-HP, Paris, France.

Background: Crohn's disease (CD) and hidradenitis suppurativa (HS), a chronic inflammatory skin disease, induce similar inflammatory lesions of the groin and gluteal area. Both diseases are characterised by an inadequate immune response to commensal bacteria in genetically predisposed subjects and can be associated.

Aim: To assess whether HS was associated with clinical and prognostic factors in CD. Read More

J Am Acad Dermatol 2020 Jun 6. Epub 2020 Jun 6.

Division of Dermatology, Harbor-UCLA Medical Center, Torrance, CA; Department of Medicine, The Lundquist Institute, Torrance, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA. Electronic address:

Pediatr Dermatol 2020 Jun 10. Epub 2020 Jun 10.

Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, USA.

Background: Current literature addressing dermatologic conditions associated with Down syndrome is limited, with emphasis on rare skin conditions and lack of consensus on the incidence of more common disorders.

Objective: We sought to evaluate dermatologic conditions in patients with Down syndrome diagnosed and managed by dermatologists.

Methods: This was a retrospective analysis of 101 pediatric and adult patients with Down syndrome seen by the University of Massachusetts Dermatology Department between 2008 and 2018. Read More

J Dermatol Sci 2020 May 22. Epub 2020 May 22.

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Physiopathology and Transplantation, Università degli Studi di Milano Via Pace 9, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. Electronic address:

Background: Diagnosis of pyoderma gangrenosum, acne and hidradenitis suppurativa (PASH) and pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH) patients, in spite of recently identified genetic variations, is just clinical, since most patients do not share the same mutations, and the mutations themselves are not informative of the biological pathways commonly disrupted in these patients.

Objective: To reveal genetic changes more closely related to PASH and PAPASH etiopathogenesis, identifying novel common pathways involved in these diseases.

Methods: Cohort study on PASH (n = 4) and PAPASH (n = 1) patients conducted using whole exome sequencing (WES) approach and a novel bioinformatic pipeline aimed at discovering potentially candidate genes selected from density mutations and involved in pathways relevant to the disease. Read More

Clin Exp Dermatol 2020 Jun 9. Epub 2020 Jun 9.

4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.

The emerging situation of patients with moderate-to-severe hidradenitis suppurativa (HS) non-eligible for or not responding to adalimumab generates the unmet need for new therapies. In a previous small-scale randomized clinical trial, MABp1 (also known as bermekimab) showed 60% treatment efficacy compared to 10% of placebo in such patient population. Eight of patients originally randomized to placebo treatment were allowed to participate in an open-label extension (OLE) treatment with MABp1 7. Read More

Dermatology 2020 Jun 9:1-8. Epub 2020 Jun 9.

Private practice, Paris, France.

Background: Although not rare, hidradenitis suppurativa (HS) is often under-recognized by physicians. The diagnosis of HS is clinical via the recognition of lesions typical of the disease, but universally accepted definitions of these latter are currently lacking, which means that certain severity scores employed for HS classification/management are used differently by different physicians. Our aim was to develop a set of descriptive definitions and associated images of HS lesions, in order to enable doctors to better recognize and evaluate the disease. Read More

Acta Derm Venereol 2020 Jun 18;100(13):adv00193. Epub 2020 Jun 18.

Dermatology Outpatient Office Dr. Daniela Kasche, Hamburg, Germany.

Breast J 2020 Jun 9. Epub 2020 Jun 9.

Department of Breast Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Br J Dermatol 2020 Jun 8. Epub 2020 Jun 8.

Department of Dermatology & Wound Healing, Division of Infection and Immunity, Cardiff University, University Hospital of Wales, 3 rd Floor Glamorgan House, Heath Park, Cardiff, CF14 4XN, U.K.

A previous survey demonstrated the management of hidradenitis suppurativa (HS) in the UK in 2014 and subsequently, in 2018, the first UK guidelines for the management of HS were published. We recently repeated the survey to evaluate whether there has been a change in the management of HS influenced by the guidelines and new HS treatment evidence. Read More

J Family Med Prim Care 2020 Mar 26;9(3):1448-1452. Epub 2020 Mar 26.

Department of Family Medicine, Ministry of Health, Jeddah, Saudi Arabia.

Context: Hidradenitis suppurativa is a noncontagious, inflammatory, chronic and recurrent disease. The prevalence of HS is estimated to be between less than 1 and 4%. It is more common in females than males at a 2:1 ratio. Read More

Exp Ther Med 2020 Jul 30;20(1):38-41. Epub 2019 Oct 30.

Department of Pathology, Colentina Clinical Hospital, 020125 Bucharest, Romania.

Suppurative hidradenitis and pyoderma gangrenosum are rare disorders that can be seen isolated or even more rare, as part of different autoinflammatory syndromes: Pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH), pyoderma gangrenosum, acne, pyogenic arthritis, and hidradenitis suppurativa (PAPASH) or psoriatic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PsAPASH). Although they have different clinical features, suppurative hidradenitis and pyoderma gangrenosum seem to share similar pathogenic pathways involving a dysregulated innate immune system, with neutrophilic inflammation, mediated by IL-1β, controlled by NALP3 inflammasome pathway. We report a case of a 53-year-old male patient previously diagnosed with HS in inguinal-scrotal area that developed rapidly after a traumatic injury on his left anterior calf, a painful inflammatory plaque with pustules on the surface that rapidly progressed (24-48 h) to form ulcers. Read More

Front Immunol 2020 20;11:847. Epub 2020 May 20.

Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition, clinically characterized by boiled cysts, comedones, abscesses, hypertrophic scars, and/or sinus tracts typically in the apocrine-gland-rich areas such as the axillae, groin, and/or buttocks. Although its precise pathogenic mechanisms remain unknown, I herein emphasize the importance of the following three recent discoveries in the pathogenesis of HS: First, heterozygous loss-of-function mutations in the genes encoding γ-secretase, including , and , have been identified in some patients with HS. Such genetic alterations result in hyperkeratosis, dysregulated hair follicle differentiation, and cyst formation via aberrant Notch signaling. Read More

Case Rep Dermatol 2020 May-Aug;12(2):83-91. Epub 2020 May 5.

Department of Dermatology, Alpert Medical School, Brown University, Providence, Rhode Island, USA.

Mannose-binding lectin (MBL) deficiency is associated with recurrent infections, autoimmune and inflammatory skin disease, and vascular complications. MBL deficiency is not a recognized comorbidity in hidradenitis suppurativa (HS); the latter is associated with the group of autoinflammatory disorders. A 32-year-old woman presented with a history of recurrent painful, deep-seated abscesses and pustular lesions since the age of 13 years. Read More

Curr Eye Res 2020 Jun 7:1-8. Epub 2020 Jun 7.

Department of Dermatology, Venereology and Allergology, University Hospital Würzburg , Würzburg, Germany.

Aim Of The Study: Hidradenitis suppurativa (HS) and psoriasis vulgaris (PSO) are chronic inflammatory dermatoses in which proinflammatory cytokines, such as IL-17, play a central role. The prevalence of keratoconjunctivitis sicca (KCS) is commonly higher in PSO than in healthy individuals. This study was thus set up to investigate the prevalence of KCS among patients with HS. Read More

J Dermatolog Treat 2020 Jun 11:1-4. Epub 2020 Jun 11.

Unidad de Gestión Clínica de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Puerta del Mar, Cádiz, Spain.

Dermatol Ther (Heidelb) 2020 Jun 4. Epub 2020 Jun 4.

Novartis Pharma AG, Basel, Switzerland.

Introduction: Hidradenitis suppurativa (HS) is a chronic, debilitating, and inflammatory skin disease. The epidemiology of HS varies greatly, with an estimated prevalence ranging from 0.03% to 4% worldwide. Read More